Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19

Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19

ObjectivesComparative analysis between different monoclonal antibodies (mAbs) against SARS-CoV-2 are lacking. We present an emulation trial from observational data to compare effectiveness of Bamlanivimab/Etesevimab (BAM/ETE) and Casirivimab/Imdevimab (CAS/IMD) in outpatients with early mild-to-mode...

Full description

Bibliographic Details
Main Authors: Valentina Mazzotta, Alessandro Cozzi-Lepri, Francesca Colavita, Simone Lanini, Silvia Rosati, Eleonora Lalle, Ilaria Mastrorosa, Claudia Cimaglia, Alessandra Vergori, Nazario Bevilacqua, Daniele Lapa, Andrea Mariano, Aurora Bettini, Chiara Agrati, Pierluca Piselli, Enrico Girardi, Concetta Castilletti, Anna Rosa Garbuglia, Francesco Vaia, Emanuele Nicastri, Andrea Antinori
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Immunology
Subjects:
monoclonal antibodies
SARS-COV-2
COVID-19
casirivimab/imdevimab
bamlanivimab/etesevimab
early treatment for COVID-19
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.868020/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.868020/full

Similar Items